Company: Aspen Pharmacare
Country: South Africa
Sector: Pharmaceuticals: Major
CEO: Stephen Saad (Group Chief Executive, co-founder)
Website: https://www.aspenpharma.com
Careers Page: Not publicly listed
LinkedIn: Not publicly listed
Email: Not publicly listed
Headquarters: La Lucia Ridge, uMhlanga, KwaZulu-Natal, South Africa
Founded: 1997 (current corporate entity; predecessor Lennon Limited dates to 1850)
Valuation/Revenue: $2,484.8m revenue; $3,972.7m market value (African Business Top 250, 2025); ~R40.7bn (~$2.36bn) revenue FY2023 per Wikipedia
Aspen Pharmacare is a South African multinational pharmaceutical manufacturer, widely described as the largest pharmaceutical company in Africa, producing branded and generic medicines, sterile injectables and active pharmaceutical ingredients across a global manufacturing network. It is listed on the Johannesburg Stock Exchange and led by co-founder Stephen Saad.
What Does Aspen Pharmacare Do?
Aspen manufactures and markets a broad range of pharmaceutical products, including sterile injectables, oral solid-dose medicines, liquids, semi-solids, biologicals and active pharmaceutical ingredients, sold under both branded and generic labels. Its manufacturing footprint spans 23 facilities across 15 sites globally, giving it significant scale in anaesthetics and anticoagulants in particular, segments the company has deliberately built up as part of a strategic shift toward specialty therapeutics. Around two-thirds of Aspen’s revenue is generated from emerging markets, reflecting both its African heritage and its deliberate strategy of serving price-sensitive, high-growth healthcare markets that many multinational pharma majors underserve.
How Big Is Aspen Pharmacare?
African Business magazine’s 2025 Top 250 ranking put Aspen’s revenue at roughly $2.48 billion, with a market value of about $3.97 billion, ranking it 64th among Africa’s largest companies by revenue. Separately, Wikipedia-sourced figures for fiscal year 2023 put revenue at approximately R40.7 billion (about $2.36 billion), with net income of R16.8 billion and total assets of R134.3 billion, while a Daily Investor feature has referred to Aspen as “the man who built a R108 billion pharmaceutical company,” indicative of the scale of its JSE market capitalisation.
Is Aspen Pharmacare Legit?
Yes. Aspen is one of the most established and closely tracked pharmaceutical companies on the JSE, with decades of manufacturing and regulatory history, global supply agreements (including prior COVID-19 vaccine manufacturing partnerships), and consistent public financial reporting as a listed company.
Who Is the CEO of Aspen Pharmacare?
Stephen Saad is Aspen’s Group Chief Executive and co-founder, having built the company from its 1997 roots (itself tracing back to the Lennon Limited pharmaceutical business founded in 1850) into Africa’s largest pharmaceutical manufacturer. Saad remains one of South Africa’s most prominent listed-company executives and a significant Aspen shareholder in his own right.
Where Is Aspen Pharmacare Headquartered?
Aspen’s global headquarters is in La Lucia Ridge, uMhlanga, in KwaZulu-Natal, South Africa, with additional major operational and manufacturing hubs internationally.
Is Aspen Pharmacare Publicly Traded?
Yes, Aspen has been listed on the Johannesburg Stock Exchange (JSE: APN) since 1998, and it is regularly counted among the largest healthcare companies on the exchange by market capitalisation.
What Has Aspen Pharmacare Been in the News For Recently?
Aspen’s biggest recent acquisition was the purchase of Sandoz’s Chinese business in December 2023, deepening its manufacturing and market presence in China. Looking ahead, in January 2026 reporting indicated founder Stephen Saad was eyeing Canada as a first proving ground for generic versions of GLP-1 weight-loss drugs such as Ozempic, positioning Aspen to compete in one of the pharmaceutical industry’s fastest-growing categories as key patents begin to expire. This pivot toward specialty and high-growth therapeutic areas, alongside its established anaesthetics and anticoagulants businesses, represents Aspen’s core strategic direction into the second half of the 2020s.
What Is Aspen Pharmacare’s Manufacturing Footprint?
Aspen operates 23 manufacturing facilities across 15 sites worldwide, giving it a genuinely global production base for a company headquartered in South Africa – a rarity among African pharmaceutical companies. This footprint has allowed Aspen to serve as a contract manufacturer for other pharmaceutical companies at scale, including a widely publicised partnership to manufacture COVID-19 vaccines for Johnson & Johnson at its Gqeberha (Port Elizabeth) facility during the pandemic, which put Aspen’s manufacturing capabilities on the global stage.
How Does Aspen Pharmacare Compare to Its Competitors?
Aspen competes with both global generics manufacturers such as Sandoz, Teva and Viatris, and with specialty pharmaceutical companies in its focus areas of anaesthetics and anticoagulants. Its emerging-markets orientation – with roughly two-thirds of revenue from outside developed Western markets – differentiates it from Western-headquartered generics players that are typically more concentrated in the US and Europe, giving Aspen a distinct competitive niche in markets like Sub-Saharan Africa, Latin America and parts of Asia.
Links
Website: https://www.aspenpharma.com
Careers Page: Not found
LinkedIn: Not found
Email: Not publicly listed
FAQ
Is Aspen Pharmacare the largest pharmaceutical company in Africa? Yes, it is widely described as such given its manufacturing scale and market reach.
Who is the CEO of Aspen Pharmacare? Stephen Saad, Group Chief Executive and co-founder.
Where is Aspen Pharmacare headquartered? La Lucia Ridge, uMhlanga, KwaZulu-Natal, South Africa.
Is Aspen Pharmacare publicly traded? Yes, on the Johannesburg Stock Exchange (JSE: APN) since 1998.
How old is Aspen Pharmacare? The current entity dates to 1997, though its roots trace to Lennon Limited, founded in 1850.
Is Aspen Pharmacare making generic Ozempic? As of early 2026, the company was reportedly exploring entry into generic GLP-1 weight-loss drugs, starting with the Canadian market.